MYD88 or TNFAIP3 mutations correlated with improved progression-free survival (PFS). KMT2D mutations trended to worse PFS….All 8 of these patients with tumors harboring mutations of MYD88 or TNFAIP3 achieved an objective response and had prolonged PFS (median PFS, NR vs 11.1 months; P= 0.008...In summary, the correlative studies described herein have demonstrated that mutations in MYD88 and TNFAIP3 associate with improved PFS, and mutations in KMT2D may associate with reduced PFS for patients with rrMZL treated with zanubrutinib.